TOTALLY SYNTHETIC ANALOGUES OF SIASTATIN B

II. OPTICALLY ACTIVE PIPERIDINE DERIVATIVES HAVING TRIFLUOROACETAMIDE AND HYDROXYACETAMIDE GROUPS AT C-2

Yoshio Nishimura, Toshiaki Kudo, Shinichi Kondo and Tomio Takeuchi

Institute of Microbial Chemistry,
3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan

(Received for publication November 20, 1991)

Siastatin B analogues, optically active 2-(trifluoroacetamide)-3,4,5-trihydroxypiperidines having nitromethyl, aminomethyl and carboxyl branched groups at C-5, and (+)-(2R,3R,4R,5S)-5-(aminomethyl)-3,4,5-trihydroxy-2-(hydroxyacetamido)piperidine have been obtained total synthetically from D-ribo-1,4-lactone. Some analogues have inhibitory activity against some glycosidases, and (+)-(2R,3R,4R,5S)-2-(trifluoroacetamido)-3,4,5-trihydroxypiperidine-5-carboxylic acid showed a marked inhibitory activity against β-glucuronidase.

Siastatin B (1), a neuraminidase inhibitor isolated from a Streptomyces culture,1) was totally synthesized from L-ribose and the absolute configuration was related with that of sialic acid (N-acetylneuraminic acid, 2) by us (Fig. 1).2,3) In our studies on siastatin B analogues, some optically active compounds were synthesized, and (2R,3R,4R,5S)-2-acetamido-3,4,5-trihydroxy-5-(nitromethyl)piperidine and its enantiomer inhibiting α-glucosidase and (2R,3R,4R,5R)-2-acetamido-3,4,5-trihydroxypiperidine-5-carboxylic acid inhibiting β-glucuronidase were obtained.4) In this paper, we describe the total syntheses of analogues of 1, namely, (2R,3R,4R,5S)-2-(trifluoroacetamido)-3,4,5-trihydroxypiperidines and their enantiomers having nitromethyl (3 and 4), aminomethyl (5 and 6) and carboxyl (7 and 8) groups at C-5, and (2R,3R,4R,5R)-5-(aminomethyl)-3,4,5-trihydroxy-2-(hydroxyacetamido)piperidine (9).

Synthesis

In the course of our study4) of the relationship between structure and biological activity, we were interested in the conversion of the functional group at the C-2 position, affecting the function of the imino group of the piperidine ring. The imino group probably interacts with the glycopyranosyl binding site to inhibit the enzymatic process. Thus, compounds (3~8) were effectively prepared from (+)-(2R,3R,4R,5S)-N-(tert-butoxycarbonyl)-5-O-(tert-butyldimethylsilyl)-3,4,5-trihydroxy-3,4-O-isopropylidene-2-phthal-
imidopiperidine (10) and its antipode (11) by similar reaction sequences to that used for the synthesis of 1.\(^2\) Treatment of 10 with hydrazine and subsequent treatment with ethyl trifluoroacetate and diisopropyl-ethylamine in \(N,N\)-dimethylformamide (DMF) gave the trifluoroacetamide 12 in 92% yield. Removal of the tert-butyldimethylsilyl group with tetrabutylammonium fluoride and oxidation of the resulting hydroxyl group of 13 with ruthenium tetroxide produced ketone 14 in a good yield. Condensation of 14 with nitromethane\(^5\) using sodium hydride in 1,2-dimethoxyethane gave adduct 15 stereospecifically in 74% yield. The \(S\)-configuration at the C-5 position was assigned by analogy with the stereochemistry of \((-)-(2R,3S,4S,5R)-2\)-acetamido-\(N\)-(tert-butoxycarbonyl)-3,4,5-trihydroxy-3,4-\(O\)-isopropylidene-5-

Scheme 1.

\[\begin{align*}
\text{TBDMS} = & (\text{CH}_3)_2\text{CSi(}\text{CH}_3)_2^- \\
\text{Boc} = & (\text{CH}_3)_2\text{COC}=\text{O} \\
\text{TFA} = & \text{CF}_3\text{C}=\text{O}
\end{align*}\]
(nitromethyl)piperidine which had been determined by the X-ray crystallographic analysis shown in the preceding paper. A small coupling constant ($J < 2$ Hz) between 2-H and 3-H in the $^1$H NMR spectrum is indicative of the half-chair or C$_2^*$-conformer of 15. Removal of protecting groups in 15 with 4 M HCl in dioxane afforded (+)-(2R,3R,4R,5S)-2-(trifluoroacetamido)-3,4,5-trihydroxy-5-(nitromethyl)piperidine (3) in 90% yield. Catalytic reduction of 15 with Raney Ni (compound 16) followed by removal of protecting groups with acid furnished ( + )-(2R,3R,4R,5R)-5-(aminomethyl)-2-(trifluoroacetamido)-3,4,5-trihydroxypiperidine (5) in a good yield. Ninhydrin oxidation of the aminomethyl group of 16 to the aldehyde group and subsequent oxidation with sodium chlorite gave the carboxylic acid 17, which was converted upon acid treatment into (+)-(2R,3R,4R,5R)-2-(trifluoroacetamido)-3,4,5-trihydroxypiperidine-5-carboxylic acid (7) in a good yield (Scheme 1).

The corresponding antipodes (4, 6 and 8) were also obtained from 11 by the same sequence mentioned above (Scheme 2).

On the other hand, 9 was straightforwardly obtained from intermediate 16 (Scheme 3). Protection of the aminomethyl group in 16 with tert-butoxycarbonyl group (compound 18) followed by removal of the N-trifluoroacetyl group gave 19 in 80% yield. Coupling of 19 with glycolic acid by use of 1,3-dicyclohexyl-
Table 1. Inhibition (%) of siastatin B (1) and its analogues at 100 µg/ml against glycosidases.

<table>
<thead>
<tr>
<th>Compound</th>
<th>α-Glucosidase (yeast)</th>
<th>β-Glucosidase (almond)</th>
<th>α-Mannosidase (soybean)</th>
<th>β-Glucuronidase (bovine liver)</th>
<th>α-Amylase (porcine pancreas)</th>
<th>β-Amylase (sweet potato)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>24</td>
<td>2</td>
<td>85 (15.5)</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>88 (2.2)</td>
<td>58 (60.0)</td>
<td>0</td>
<td>14</td>
<td>0</td>
<td>77 (16.8)</td>
</tr>
<tr>
<td>5</td>
<td>90 (1.9)</td>
<td>39</td>
<td>5</td>
<td>13</td>
<td>0</td>
<td>73 (10.0)</td>
</tr>
<tr>
<td>6</td>
<td>90 (1.6)</td>
<td>38</td>
<td>1</td>
<td>43</td>
<td>0</td>
<td>70 (16.5)</td>
</tr>
<tr>
<td>7</td>
<td>87 (7.7)</td>
<td>22</td>
<td>7</td>
<td>100 (0.02)</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>8</td>
<td>81 (5.3)</td>
<td>10</td>
<td>5</td>
<td>74 (37.0)</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>9</td>
<td>90 (4.4)</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>45</td>
</tr>
</tbody>
</table>

( ): IC₅₀, µg/ml.

carbodiimide (DCC) afforded N-glycolyl compound 20, which was transformed into (+)-(2R,3R,4R,5R)-5-(aminomethyl)-3,4,5-trihydroxy-2-(hydroxyacetamido)piperidine (9) in a good yield upon treatment with acid (Scheme 3).

The $^1$H NMR spectra of compounds 15, 16, 17, 18, 19 and 20 show small coupling constants ($J = \sim 2$ Hz) between 2-H and 3-H, while those of 3, 5, 7 and 9 show large coupling constants ($J = \sim 10$ Hz). These facts indicate that the fused isopropylidene and the bulky $N$-ter/-butoxycarbonyl groups of compounds having branched substituents at the C-5 position are responsible for a conformational flip from C$_2$-type to C$_3$-type or half-chair type. Similar results were observed in the previous syntheses.$^{3,4}$

Biological Activities

As shown in Table 1, all analogues tested showed inhibitory activity against α-glucosidase from yeast, and some of them also inhibited β-amylase from sweet potato. Remarkably, 7 affected strongly β-glucuronidase from bovine liver. No analogues showed inhibitory activity against other glycosidases (α-mannosidase from soybean, α-amylase from porcine pancreas) as well as sialidases isolated from microorganisms (Streptococcus sp., Arthrobacter ureafaciens and Clostridium perfringens) and A/Aichi/2/68 (H3N2) strain of influenza virus. Further evaluation of the biological activities of these analogues are under investigation.

Experimental

General Methods

Melting points were determined with a Yanagimoto apparatus and are uncorrected. IR spectra were determined on a Hitachi Model 260-10 spectrophotometer. Optical rotations were measured with a Perkin-Elmer Model 241 polarimeter. $^1$H NMR spectra were recorded with Jeol GX-400 and JNM-EX270 spectrometers. Chemical shifts are expressed in δ values (ppm) with tetramethylsilane as an internal standard. Mass spectra were taken by a Hitachi M-80H for secondary ionization and a Jeol SX102 in the FAB mode.

(2S,3R,4R,5S)-N-((tert-Butoxycarbonyl)-5-O-((tert-butyldimethylsilyl)-2-(trifluoroacetamido)-3,4,5-trihydroxy-3,4-O-isopropylidene)piperidine (12)

To a solution of 10 (2.6 g) in MeOH (130 ml) was added anhydrous hydrazine (5 ml), and the mixture was stirred at 30°C overnight. Filtration of the resulting precipitate and evaporation of the filtrate gave a viscous solid. The residue was taken up in ether, and the ethereal solution was evaporated to give an oil (2.1 g). The oil was dissolved in DMF (7.1 ml). To the solution were added diisopropylethylamine (7.1 ml) and ethyl trifluoroacetate (3.54 ml), and then the mixture was stirred at room temperature overnight.
Evaporation of the solvent gave an oil, which was dissolved in CH₂Cl₂. The solution was washed with NaCl-saturated aqueous solution, dried over MgSO₄, and filtered. Evaporation of the filtrate gave an oil, which was subjected to column chromatography on silica gel. Elution with mixture of toluene-acetone (30:1) gave 12 as a colorless oil (2.23g, 91.6%): [α]₆⁰ +39.7° (c 0.65, MeOH); IR (KBr) cm⁻¹ 3000, 2980, 2950, 2930, 2890, 2850, 1730, 1700 (sh), 1520 (sh), 1470, 1460, 1390, 1385, 1370, 1340 (sh), 1310, 1250, 1200 (sh), 1165, 1120 (sh), 1070, 990, 950, 930, 920 (sh); ¹H NMR (CDCl₃, 400 MHz) δ 0.91 (6H, s, -Si(CH₃)₂), 1.35, 1.50 (each 3H, s, isopropylidene), 0.47 (9H, s, -Si(CH₃)₃), 1.62 (9H, s, COOC(CH₃)₃), 3.30 (1H, t, J=11.5Hz, 6-Hax), 3.45 (1H, dd, J=11.5 and 5Hz, 6-Heq), 3.99 (1H, ddd, J=11.5, 5 and 3.6Hz, 5-H), 4.41 (1H, dd, J=7 and 3.6Hz, 4-H), 4.52, (1H, dd, J=7 and 4Hz, 3H, 5.45 (1H, brs, 2-H) and 8.00 (1H, s, -NHCOCF₃); FAB-MS m/z 499 (M+H)+, 443, 386, 286, 170 and 57.

(25'R,3'S,4'R,5'S)-7-(D-Butoxycarbonyl)-2-(trifluoroacetamido)-3,4,5-trihydroxy-3,4-O-isopropylidene-5-(nitromethyl)piperidine (13)

To a solution of 12 (2.2g) in THF (110ml) was added tetrabutylammonium fluoride (1 m solution in THF, 55 ml), and the mixture was allowed to stand at room temperature overnight. Evaporation of the solvent gave an oil which was dissolved in CH₂Cl₂. The solution was washed with water, dried over MgSO₄, and filtered. Evaporation of the filtrate gave an oil which was subjected to column chromatography on silica gel. Elution with a mixture of toluene-acetone (3:1) gave 13 as a colorless oil (1.69g, 100%): [α]₆⁰ +48.2° (c 0.27, MeOH); IR (KBr) cm⁻¹ 3425, 3025, 2990, 2950, 1740, 1705 (sh), 1540, 1520, 1480, 1460, 1400, 1380, 1360, 1330 (sh), 1310, 1260, 1200 (sh), 1170, 1100 (sh), 980, 950, 900; ¹H NMR (CDCl₃, 270MHz) δ 1.40, 1.52 (each 3H, s, isopropylidene), 1.47 (9H, s, COOC(CH₃)₃), 2.35 (1H, d, J=9.9Hz, 5-OH), 3.08 (1H, t, J=11.9Hz, 6-Hax), 3.66 (1H, dd, J=11.9 and 4.6Hz, 6-Heq), 3.87 (1H, m, 5-H), 4.55 (1H, dd, J=7 and 4Hz, 4-H), 4.65 (1H, dd, J=7 and 2.3Hz, 3-H), 5.63 (1H, brs, 2-H); FAB-MS m/z 385 (M+H)+, 329, 313, 216, 172 and 57.

(25'R,3'S,4'R,5'S)-N-(tert-Butoxycarbonyl)-2-(trifluoroacetamido)-3,4,5-trihydroxy-3,4-O-isopropylidene-5-(nitromethyl)piperidine (15)

A solution of RuO₄ in CCl₄ prepared from RuO₂ (1.3g) and NaIO₄ (10.2g) in a mixture of H₂O (190ml) and CCl₄ (190ml) was added to a solution of 13 (1.4g) in CH₂Cl₂ (45ml) until the appearance of a yellow color, and the mixture was stirred at room temperature for 15 minutes. After being quenched with 2-propanol (4ml), the mixture was diluted with CH₂Cl₂. The solution was washed with water, dried over MgSO₄, and filtered. Evaporation of the filtrate gave solid 14 (1.3g). To a solution of 14 (1.3g) in a mixture of 1,2-dimethoxyethane (13ml) and nitromethane (6ml) was added NaH (90mg) at -20°C, and the mixture was stirred at room temperature for 1.5 hours. After being quenched with acetic acid, the mixture was diluted with CHCl₃. The solution was washed with NaHCO₃-saturated aqueous solution and then water and dried over MgSO₄ and filtered. The filtrate was evaporated to give a solid. The solid was recrystallized from a mixture of EtOAc and ether to give 15 as colorless crystals (1.2 g, 74%): MP 184~186°C (dec); [α]₆⁰ +60.6° (c 1.0, MeOH); IR (KBr) cm⁻¹ 3330, 3225, 2975, 2930, 1740, 1670, 1555, 1530, 1460, 1415, 1380, 1360, 1340, 1320, 1265, 1215, 1165, 1140, 1100, 1070, 1060, 980, 970, 930, 910; ¹H NMR (CDCl₃, 270 MHz) δ 1.33, 1.49 (each 3H, s, isopropylidene), 1.45 (9H, s, COOC(CH₃)₃), 3.17, 3.84 (each 1H, brd, J=12.9Hz, 6-H), 4.49 (1H, dd, J=6.9 and 2.3Hz, 3-H), 4.58 (1H, brs, 5-OH), 6.16 (1H, brd, J=8.6Hz with a small coupling, 2-H), 7.85 (1H, brd, J=8.6Hz, -NHCO-); FAB-MS m/z 444 (M+H)+, 388, 231 and 57.

(2R,3R,4R,5S)-2-(Trifluoroacetamido)-3,4,5-trihydroxy-5-(nitromethyl)piperidine (3)

Compound 15 (20mg) was dissolved in 4 M hydrogen chloride in dioxane (0.4ml), and the mixture was allowed to stand at room temperature for 2.5 hours. Another portion of 4 M hydrogen chloride in dioxane (0.4ml) was added to the mixture and then the reaction mixture was further stirred at room temperature overnight. Evaporation of the solvent gave a solid. The solid was thoroughly washed with ether to give a colorless amorphous solid of 9 as its hydrochloride (13.8mg, 90%); [α]₆⁰ +22.7° (c 0.45, H₂O); IR (KBr) cm⁻¹ 3400, 1730, 1640 (sh), 1570, 1470 (sh), 1440, 1400, 1230, 1190, 1110, 1090, 1020, 940, 920; ¹H NMR (D₂O, 400 MHz, 35°C) δ 3.33 (1H, brd with small couplings, J=13.6Hz, 6-H), 3.54 (1H, dd, J=13.6 and 1.6Hz, 6-H), 4.16 (1H, brs with small couplings, 4-H), 4.37 (1H, ddd, J=10.4, 3.2 and 1.6Hz,
THE JOURNAL OF ANTIBIOTICS  
JUNE 1992

3-H), 4.81 and 4.96 (2H, ABq, J = 12.8 Hz, -CH$_2$NO$_2$) and 5.14 (1H, dd, J = 10.4 and 1.2 Hz, 2-H); 
FAB-MS m/z 304 (M + H)$^+$, 231, 191, 75 and 57.

(2S,3R,4R,5R)-5-(Aminomethyl)-N-(tert-butoxycarbonyl)-2-(trifluoroacetamido)-3,4,5-trihydroxy-
3,4-O-isopropylidenepiperidine (16)

A solution of 15 (815 mg) in MeOH (16 ml) was hydrogenated at room temperature in the presence 
of Raney Ni under 3.5 kg/cm$^2$ pressure of hydrogen gas for 1 hour. Filtration of the catalyst and evaporation 
of the filtrate gave 16 as a colourless oil (747 mg, 98%): $\alpha = +65.8^\circ$ (c 1.0, MeOH); IR (KBr) cm$^{-1}$ 3360, 
3010, 2970, 1750, 1710, 1550, 1470, 1410, 1400, 1390 (sh), 1370, 1340, 1320, 1290, 1280, 1180, 1070, 990, 
940; $^1$H NMR (CDCl$_3$, 400 MHz) $\delta$ 1.32, 1.43 (each 3H, s, isopropylidene), 1.45 (9H, s, COOC(CH$_3$)$_3$), 
2.56, 3.00 (2H, ABq, $\delta$ = 13 Hz, -CH$_2$NO$_2$), 3.13 (1H, d, $\delta$ = 13 Hz, 6-H), 3.48 (1H, dd, $\delta$ = 13 and 1.8 Hz, 
6-H), 4.03 (1H, dd, $\delta$ = 7 and 1.8 Hz, 4-H), 4.44 (1H, dd, $\delta$ = 7 and 2.2 Hz, 3-H), 4.97 (1H, brs, OH), 6.15 
(1H, d with a small coupling, $J$ = 10 Hz, 2-H) and 8.58 (1H, brd, $J$ = 10 Hz, -NHCO-); FAB-MS m/z 414 
(M + H)$^+$, 358, 301, 245, 201 and 57.

(2R,3R,4R,5R)-5-(Aminomethyl)-2-(trifluoroacetamido)-3,4,5-trihydroxy-piperidine (5)

The procedure used for the preparation of 5 was similar to that used for the preparation of 3 from 
15; the yield of amorphous solid 5 hydrochloride was 98%: $\alpha = +17.5^\circ$ (c 0.55, H$_2$O); IR (KBr) cm$^{-1}$ 
3420, 3250 (sh), 3050, 2910, 1740, 1620, 1570, 1500, 1470, 1400, 1230, 1180, 1080, 1010, 950, 920; $^1$H NMR 
(D$_2$O, 400 MHz) $\delta$ 3.25 (1H, dd, $\delta$ = 14 and 1.6 Hz, 6-Heq), 3.26, 3.33 (2H, ABq, $\delta$ = 14.4 Hz, 5-CH$_2$), 
3.51 (1H, d, $\delta$ = MHz, 6-Hax), 4.07 (1H, dd, $\delta$ = 2.8 and 1.6 Hz, 4-H), 4.37 (1H, dd, $\delta$ = 10.8 and 2.8 Hz, 
3-H) and 5.18 (1H, d, $J$ = 10.8 Hz, 2-H); SI-MS m/z 274 (M + H)$^+$, 215, 201, 161, 75, 57 and 45.

(2S,3R,4R,5R)-N-(tert-Butoxycarbonyl)-2-(trifluoroacetamido)-3,4,5-trihydroxy-3,4-O-isopropylidenepiperidine-5-carboxylic Acid (17)

To a solution of 16 (747 mg) in a mixture of MeOH (37 ml) and water (37 ml) were added ninhydrin 
(965 mg) and NaHCO$_3$ (437 mg), and the mixture was stirred at room temperature overnight. Evaporation 
of the solvent gave a solid, which was dissolved in CHCl$_3$. The CHCl$_3$ solution was washed with 
NaCl-saturated aqueous solution, dried over MgSO$_4$, and filtered. Evaporation of the filtrate gave a solid 
which was dissolved in 2-methyl-2-propanol (8 ml). To the solution were added 2-methyl-2-butene (1.6 ml) 
and a solution of a mixture of NaClO$_2$ (1.54 g) and NaH$_2$PO$_4$ (2.14 g) in water (8 ml), and then the mixture 
was stirred at room temperature overnight. After separation of the mixture into organic and water layers, 
the water layer was extracted with CHCl$_3$. The organic layer and extract were combined and evaporated. 
The resulting oil was subjected to preparative thin-layer chromatography on silica gel, developing with a 
mixture of CHCl$_3$-MeOH (3 : 1), to give 17 as a colorless amorphous solid (332 mg, 43%): $\alpha = +36.6^\circ$ 
(c 1.0, MeOH); IR (KBr) cm$^{-1}$ 3410, 3010, 2970, 1750, 1690, 1540, 1470, 1410, 1400, 1360, 
1310, 1270, 1230, 1180, 1070, 990, 930; $^1$H NMR (CDCl$_3$, 400 MHz) $\delta$ 3.51 (1H, d, $J$ = 14 Hz, 6-H$_{eq}$), 
4.07 (1H, dd, $J$ = 2.8 and 1.6 Hz, 4-H), 4.37 (1H, dd, $J$ = 10.8 and 2.8 Hz, 3-H) and 5.18 (1H, d, $J$ = 10.8 Hz, 2-H); SI-MS m/z 451 (M + Na)$^+$, 395, 260, 238, 158, 115 and 57.

(2R,3R,4R,5R)-2-(Trifluoroacetamido)-3,4,5-trihydroxypiperidine-5-carboxylic Acid (7)

The procedures used for the preparation of 7 were similar to those used for the preparation of 3 from 
15; the yield amorphous solid 7 hydrochloride was 96%: $\alpha = +19.7^\circ$ (c 0.66, H$_2$O); IR (KBr) cm$^{-1}$ 
3430, 3350, 2950, 2870 (sh), 1750, 1730, 1575, 1450, 1410, 1280, 1190, 1185 (sh), 1110, 1105, 1100 
(sh), 1000, 965, 940, 930; $^1$H NMR (D$_2$O, 400 MHz) $\delta$ 3.38 (6H, brs, isopropylidene), 1.42 (9H, brs, COOC(CH$_3$)$_3$), 3.4~3.5, 3.5~3.7 (each 1H, brs, 6-H), 4.23 (1H, brs, 4-H), 4.38 (1H, brs, 3-H), 6.08 (1H, d with a small coupling, $J$ = 8.5 Hz, 2-H) and 8.3~8.6 (1H, brs, -NHCO-); FAB-MS m/z 289 (M + H)$^+$, 244, 177, 132, 115, 75, 57 and 45.

(2S,3R,4R,5R)-2-(Trifluoroacetamido)-3,4,5-trihydroxy-piperidine-5-carboxylic Acid-5-tert-butyl-
carbamoylamino)methyl)-2-(trifluoroacetamido)-3,4,5-trihydroxy-3,4-O-isopropylidenepiperidine (18)

To a solution of 16 (83 mg) in MeOH (1.7 ml) were added diisopropylethylamine (0.12 ml) and 
di-tert-butyldicarbonate (0.138 ml), and the mixture was stirred at room temperature for 6 hours.
Evaporation of the solvent gave an oil, which was dissolved in CH$_2$Cl$_2$. The solution was washed with water, dried over MgSO$_4$, and filtered. Evaporation of the filtrate gave an oil, which was subjected to column chromatography on silica gel. Elution with a mixture of toluene-acetone (10:1) gave 18 as a colorless oil (94mg, 91%): $[\alpha]_D^2 +37^\circ$ (c 1.0, MeOH); IR (CHCl$_3$) cm$^{-1}$ 3490, 3380, 3050, 3020, 2970, 1745, 1710, 1540 (sh), 1525, 1410, 1390, 1320, 1280 (sh), 1270, 1180, 1070, 990, 930; $^1$H NMR (CDCl$_3$, 400 MHz) $^3$ 1.32, 1.42 (each 3H, s, isopropylidene), 1.45 (9H, s, COOC(CH$_3$)$_3$), 1.48 (9H, s, COOC(CH$_3$)$_3$), 3.03 (1H, d, $J = 13$ Hz, 6-H), 3.24, 3.37 (each 1H, dd, $J = 15$ and 6Hz, 5-CH$_2$), 3.64 (1H, dd, $J = 13$ and 1.6Hz, 6-H), 4.11 (1H, dd, $J = 7$ and 1.6Hz, 4-H), 4.42 (1H, dd, $J = 7$ and 2Hz, 3-H), 5.02 (1H, brt, $J = 6$ Hz, NHCOO), 6.07 (1H, s, OH), 6.12 (1H, dd, $J = 9$ and 2Hz, 2-H) and 8.46 (1H, br d, $J = 9$ Hz, NHCOF$_3$); SI-MS m/z 514 (M+H)$^+$, 458, 402, 302, 245, 201, 75 and 57.

(2S,3R,4R,5R)-$N$-(tert-Butoxycarbonyl)-5-(tert-butoxycarbonylaminomethyl)-3,4,5-trihydroxy-2-(hydroxyacetamido)-3,4-O-isopropylidenepiperidine (20)

To a solution of 18 (94mg) in MeOH (3ml) was added a 7% aqueous solution of K$_2$CO$_3$ (5.4ml), and the mixture was stirred at room temperature overnight. Evaporation of the solvent gave an oil which was dissolved in CH$_2$Cl$_2$. The solution was washed with water, dried over MgSO$_4$, and filtered. The filtrate was evaporated to give 19 as an oil (67mg). The oil was dissolved in DMF (1.2ml), and to the solution were successively added glycolic acid (44 mg), 1-hydroxybenzotriazole hydrate (66 mg) and DCC (104mg). Then the mixture was stirred at room temperature overnight. After filtration of the resulting precipitate, evaporation of the filtrate gave an oily residue. The residue was subjected to preparative thin-layer chromatography on silica gel, developing with a mixture of CHCl$_3$ - MeOH (6:1), to give 20 as a colorless oil (59 mg, 68%): $[\alpha]_D^2 +28^\circ$ (c 0.4, MeOH); IR (CHCl$_3$) cm$^{-1}$ 3460, 3370, 2990, 2950, 1670, 1515, 1460, 1395, 1390, 1300, 1270, 1260, 1165, 1095, 1070, 960; $^1$H NMR (CDCl$_3$, 400MHz) $^3$ 1.30, 1.40 (each 3H, s, isopropylidene), 1.44 (9H, s, COOC(CH$_3$)$_3$), 1.47 (9H, s, COOC(CH$_3$)$_3$), 3.05 (1H, d, $J = 13$ Hz, 6-H), 3.22 and 3.38 (each 1H, dd, $J = 15$ and 6Hz, 5-CH$_2$), 3.60 (1H, brd with a small coupling, $J = 13$Hz, 6-H), 4.04 (2H, brs, COCH$_2$), 4.09 (1H, dd, $J = 7.5$ and 2.2Hz, 4-H), 4.42 (1H, br d with a small coupling, $J = 7.5$Hz, 3-H), 5.04 (1H, brt, $J = 6$ Hz, NHCOO), 5.73 (1H, s, OH), 6.21 (1H, br d with a small coupling, $J = 9$ Hz, 2-H) and 7.86 (1H, br d, $J = 9$ Hz, NHCO); SI-MS m/z 476 (M+H)$^+$, 402, 302, 246, 201 and 57.

(2R,3R,4R,5R)-5-(Aminomethyl)-3,4,5-trihydroxy-2-(hydroxyacetamido)piperidine (9)

The procedures used for the preparation of 9 were similar to those used for the preparation of 3 from 15; the yield of amorphous solid 9 hydrochloride was 84.6%: $[\alpha]_D^5 +28^\circ$ (c 0.45, H$_2$O); IR (KBr) cm$^{-1}$ 3400, 3050 (sh), 2910 (sh), 1680, 1630, 1540, 1465, 1230, 1100, 1130, 1030, 990, 970, 920; $^1$H NMR (D$_2$O, 400 MHz) $^3$ 3.26, 3.33 (2H, ABq, $J = 14$Hz, 5-CH$_2$), 3.27 (1H, dd, $J = 13.2$ and 1.6Hz, 6-H$_{eq}$), 3.52 (1H, d, $J = 13.2$ Hz, 6-H$_{ax}$), 4.07 (1H, dd, $J = 2.8$ and 1.6 Hz, 4-H), 4.23 (2H, s, COCH$_2$), 4.37 (1H, dd, $J = 11.2$ and 2.8Hz, 3-H) and 5.19 (1H, d, $J = 11.2$Hz, 2-H); SI-MS m/z 236 (M+H)$^+$, 201, 161, 75 and 57.

Enantiomers

The corresponding enantiomers were similarly obtained.

12 enantiomer: $[\alpha]_D^2 -42^\circ$ (c 1.0, MeOH). 13 enantiomer: $[\alpha]_D^2 -47^\circ$ (c 1.0, MeOH). 15 enantiomer: MP 192~195°C (dec); $[\alpha]_D^2 -67.9^\circ$ (c 1.0, MeOH). 16 enantiomer: $[\alpha]_D^{25} -59.4^\circ$ (c 1.0, MeOH). 17 enantiomer: $[\alpha]_D^{25} -36.5^\circ$ (c 0.88, MeOH). 6: $[\alpha]_D^{25} -17.5^\circ$ (c 0.59, H$_2$O). 8: $[\alpha]_D^{25} -19.6^\circ$ (c 0.7, H$_2$O).

Acknowledgments

The authors are grateful to the members of the Central Research Institute, MECT Corp. and the Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd. for the biological evaluation.

References

the total synthesis and absolute configuration. J. Am. Chem. Soc. 110: 7249–7250, 1988


